<p>Truffle Hound Capital LLC 在第二季度根据其最近向证券交易委员会提交的 13F 文件，收购了 InfuSystem Holdings, Inc. (NYSE:INFU - 免费报告) 的新头寸。该公司收购了 180,000 股该公司的股票，价值约为 1,123,000 美元。Truffle Hound Capital LLC 在最近的报告期末持有 InfuSystem 约 0.88% 的股份。</p>
<ul>
<li>医疗设备的未来：你不能错过的两个强力买入</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。American Century Companies Inc. 在第一季度以约 256,000 美元的价格收购了 InfuSystem 的新头寸。Voya Investment Management LLC 在第一季度以 182,000 美元的价格购买了 InfuSystem 的新头寸。汇丰控股 PLC 在第一季度以 147,000 美元的价格收购了 InfuSystem 的新头寸。Nuveen LLC 在第一季度以 465,000 美元的价格收购了 InfuSystem 的新头寸。最后，Russell Investments Group Ltd. 在第一季度将其在 InfuSystem 的股份提高了 13.1%。Russell Investments Group Ltd. 目前持有 437,891 股该公司的股票，价值 2,356,000 美元，此前在上个季度又购买了 50,877 股。71.13% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>INFU 已成为几份研究分析师报告的主题。Zacks Research 在 10 月 6 日的研究报告中将 InfuSystem 的股票评级从 “强力买入” 下调至 “持有”。Roth Capital 在 11 月 4 日的报告中重申了 “买入” 评级，并将 InfuSystem 的目标价上调至 14.00 美元（从 13.00 美元上调）。最后，Lake Street Capital 在 9 月 22 日的报告中开始覆盖 InfuSystem。他们对该股票设定了 “买入” 评级和 15.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，两位给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，InfuSystem 目前的共识评级为 “买入”，共识目标价为 14.50 美元。</p>
<p><strong>阅读我们关于 INFU 的最新研究报告</strong></p>
<h2>内部交易活动</h2>
<p>在其他新闻中，董事 Scott Shuda 于 8 月 22 日星期五出售了 5,752 股该公司的股票。股票以平均价格 9.67 美元出售，总交易额为 55,621.84 美元。出售完成后，该董事直接持有 94,000 股该公司的股票，价值 908,980 美元。这代表了他们持股比例的 5.77% 的下降。该交易在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。11.40% 的股票由内部人士持有。</p>
<h2>InfuSystem 股票下跌 2.0%</h2>
<p>NYSE INFU 周二开盘价为 9.32 美元。InfuSystem Holdings, Inc. 的 12 个月低点为 4.61 美元，12 个月高点为 11.04 美元。该公司的市值为 1.8953 亿美元，市盈率为 155.36，贝塔值为 1.80。该公司的 50 日简单移动平均线为 10.00 美元，200 日简单移动平均线为 7.96 美元。该公司的债务与股本比率为 0.50，流动比率为 1.98，速动比率为 1.59。</p>
<h2>关于 InfuSystem</h2>
<p>(免费报告)</p>
<p>InfuSystem Holdings, Inc. 通过其子公司在美国和加拿大提供输液泵及相关产品和服务。该公司分为两个部门，患者服务和设备解决方案。它向肿瘤科、输液和医院门诊化疗诊所提供电子便携式输液泵及相关一次性供应包，用于治疗各种癌症，包括结直肠癌、疼痛管理和其他疾病状态。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 InfuSystem</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>随着 AI 驱动存储需求，Seagate 股票可能飙升</li>
<li>国会股票交易跟踪</li>
<li>惠而浦的最坏时刻可能已经过去——未来有机会</li>
<li>你应该投资于便士股票吗？</li>
<li>这三只被打压的股票可能是你本季度最佳的购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 InfuSystem 吗？</h2>
<p>在你考虑 InfuSystem 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 InfuSystem 并不在名单上。</p>
<p>虽然 InfuSystem 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

InfuSystems控股

<p>根据向美国证券交易委员会（SEC）提交的 13F 文件，Truffle Hound Capital LLC 在第二季度收购了 180,000 股 InfuSystem Holdings, Inc.，价值约为 1,123,000 美元。这次收购代表了 InfuSystem 约 0.88% 的股份。该公司在美国和加拿大提供输液泵及相关服务。分析师对 InfuSystem 的共识评级为 “买入”，目标价格为 14.50 美元</p>

<p>Truffle Hound Capital LLC acquired a new position in shares of InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm acquired 180,000 shares of the company's stock, valued at approximately $1,123,000. Truffle Hound Capital LLC owned about 0.88% of InfuSystem at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Truffle Hound Capital LLC 在第二季度根据其最近向证券交易委员会提交的 13F 文件，收购了 InfuSystem Holdings, Inc. (NYSE:INFU - 免费报告) 的新头寸。该公司收购了 180,000 股该公司的股票，价值约为 1,123,000 美元。Truffle Hound Capital LLC 在最近的报告期末持有 InfuSystem 约 0.88% 的股份。</p>
</div><ul>
<li>The Future of Medical Devices: Two Strong Buys You Can't Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗设备的未来：你不能错过的两个强力买入</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of the business. American Century Companies Inc. acquired a new position in InfuSystem during the 1st quarter valued at about $256,000. Voya Investment Management LLC bought a new position in shares of InfuSystem in the first quarter worth $182,000. Hsbc Holdings PLC acquired a new position in shares of InfuSystem during the first quarter valued at $147,000. Nuveen LLC acquired a new position in shares of InfuSystem during the first quarter valued at $465,000. Finally, Russell Investments Group Ltd. raised its stake in shares of InfuSystem by 13.1% during the first quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company's stock valued at $2,356,000 after purchasing an additional 50,877 shares in the last quarter. 71.13% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。American Century Companies Inc. 在第一季度以约 256,000 美元的价格收购了 InfuSystem 的新头寸。Voya Investment Management LLC 在第一季度以 182,000 美元的价格购买了 InfuSystem 的新头寸。汇丰控股 PLC 在第一季度以 147,000 美元的价格收购了 InfuSystem 的新头寸。Nuveen LLC 在第一季度以 465,000 美元的价格收购了 InfuSystem 的新头寸。最后，Russell Investments Group Ltd. 在第一季度将其在 InfuSystem 的股份提高了 13.1%。Russell Investments Group Ltd. 目前持有 437,891 股该公司的股票，价值 2,356,000 美元，此前在上个季度又购买了 50,877 股。71.13% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>INFU has been the topic of several research analyst reports. Zacks Research cut shares of InfuSystem from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 6th. Roth Capital reiterated a &#34;buy&#34; rating and issued a $14.00 price objective (up from $13.00) on shares of InfuSystem in a report on Tuesday, November 4th. Finally, Lake Street Capital began coverage on InfuSystem in a report on Monday, September 22nd. They set a &#34;buy&#34; rating and a $15.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, InfuSystem presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $14.50.</p>
<div class="lb-trans"><p>INFU 已成为几份研究分析师报告的主题。Zacks Research 在 10 月 6 日的研究报告中将 InfuSystem 的股票评级从 “强力买入” 下调至 “持有”。Roth Capital 在 11 月 4 日的报告中重申了 “买入” 评级，并将 InfuSystem 的目标价上调至 14.00 美元（从 13.00 美元上调）。最后，Lake Street Capital 在 9 月 22 日的报告中开始覆盖 InfuSystem。他们对该股票设定了 “买入” 评级和 15.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，两位给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，InfuSystem 目前的共识评级为 “买入”，共识目标价为 14.50 美元。</p>
</div><p><strong>Read Our Latest Research Report on INFU</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 INFU 的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director Scott Shuda sold 5,752 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the sale, the director directly owned 94,000 shares of the company's stock, valued at $908,980. This represents a 5.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 11.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Scott Shuda 于 8 月 22 日星期五出售了 5,752 股该公司的股票。股票以平均价格 9.67 美元出售，总交易额为 55,621.84 美元。出售完成后，该董事直接持有 94,000 股该公司的股票，价值 908,980 美元。这代表了他们持股比例的 5.77% 的下降。该交易在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。11.40% 的股票由内部人士持有。</p>
</div><h2>InfuSystem Stock Down 2.0%</h2>
<div class="lb-trans"><h2>InfuSystem 股票下跌 2.0%</h2>
</div><p>NYSE INFU opened at $9.32 on Tuesday. InfuSystem Holdings, Inc. has a 12 month low of $4.61 and a 12 month high of $11.04. The company has a market capitalization of $189.53 million, a P/E ratio of 155.36 and a beta of 1.80. The company's 50 day simple moving average is $10.00 and its 200 day simple moving average is $7.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59.</p>
<div class="lb-trans"><p>NYSE INFU 周二开盘价为 9.32 美元。InfuSystem Holdings, Inc. 的 12 个月低点为 4.61 美元，12 个月高点为 11.04 美元。该公司的市值为 1.8953 亿美元，市盈率为 155.36，贝塔值为 1.80。该公司的 50 日简单移动平均线为 10.00 美元，200 日简单移动平均线为 7.96 美元。该公司的债务与股本比率为 0.50，流动比率为 1.98，速动比率为 1.59。</p>
</div><h2>About InfuSystem</h2>
<div class="lb-trans"><h2>关于 InfuSystem</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.</p>
<div class="lb-trans"><p>InfuSystem Holdings, Inc. 通过其子公司在美国和加拿大提供输液泵及相关产品和服务。该公司分为两个部门，患者服务和设备解决方案。它向肿瘤科、输液和医院门诊化疗诊所提供电子便携式输液泵及相关一次性供应包，用于治疗各种癌症，包括结直肠癌、疼痛管理和其他疾病状态。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than InfuSystem</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Seagate Stock Could Soar as AI Drives Storage Demand</li>
<li>Following Congress Stock Trades</li>
<li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li>
<li>Should You Invest in Penny Stocks?</li>
<li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 InfuSystem</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>随着 AI 驱动存储需求，Seagate 股票可能飙升</li>
<li>国会股票交易跟踪</li>
<li>惠而浦的最坏时刻可能已经过去——未来有机会</li>
<li>你应该投资于便士股票吗？</li>
<li>这三只被打压的股票可能是你本季度最佳的购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlORlU" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INFU"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InfuSystem Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 InfuSystem 吗？</h2>
</div><p>Before you consider InfuSystem, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 InfuSystem 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 InfuSystem 并不在名单上。</p>
</div><p>While InfuSystem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 InfuSystem 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Truffle Hound Capital LLC 购入了 InfuSystem Holdings, Inc.的新股份